New developments in the treatment of Alzheimer's disease.
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000097:blood; D001284:Atrophy; D015415:Biomarkers / Q000097:blood; D001921:Brain / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D003430:Cross-Sectional Studies; D003952:Diagnostic Imaging; D018450:Disease Progression; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D008875:Middle Aged; D009483:Neuropsychological Tests; D010446:Peptide Fragments / Q000097:blood; D011157:Population Dynamics; D012307:Risk Factors
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42); D008559:Memantine